

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **EGF Theramed Health Corp.** (the “Issuer”).

Trading Symbol: **TMED.**

Number of Outstanding Listed Securities: **1,179,546.**

Date: **December 3, 2019.**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

FORM 7 – MONTHLY PROGRESS REPORT

January 2015

Page 1

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer is working with its hardware technologies and software applications towards providing a personalized health care system and the company has been in discussions with an engineer on furthering development of its medical products exchange app and determining the best way to utilize it with a focus on natural products a component to a personalized wellness system.

It continued to discuss the possibility of continuing its operating arrangement despite being in default and termination by the principals who hold the Intellectual Property (IP) of a Timed Release Excipient Carrier System designed to improve bioavailability and solubility of hard to dissolve Active Pharmaceutical Ingredients (APIs) /materials such as CBDs.

The Issuer is also working with its advisors to offer consulting with other companies for medical technology and equipment protocols and laboratory SOPs.

The Issuer also continues assisting its subsidiary Western Agri in developing out its processing and extraction facility as part of its Natural Plants and Herbs Health System vertical. The company has been working closely with its advisors for the development of the extraction facility,

The Issuer conducted a name change and consolidation. The company name has now changed and is rebranded as EGF Theramed Health Corp.

2. Provide a general overview and discussion of the activities of management.

Management continues to pursue opportunities in the healthcare business. While the primary focus is still on customizing hardware technologies and software applications towards providing personalized health solutions for common health issues, management has been exposed to and presented with a number of health/medical opportunities, interesting software technologies, and other

potential businesses. The Issuer also continues to evaluate business opportunities in an endeavor to increase shareholder value. As identified above, management has been active in arranging financing for the Issuer, working on rectifying its default with the principals of the Excipient Carrier Delivery System, developing its lab extraction facility in Nevada for plant oils, and its medical products exchange app. Management has also been evaluating other medical product sales channels. There are no other matters to report.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The Issuer did not develop any new products or services during the month of November 2019.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

The Issuer did not discontinue any products or services during the month of November 2019.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Issuer did not enter into any new business relationships during the month of November 2019.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

On November 6, 2019 the Issuer was notified of the default and termination of its joint venture to develop intellectual property for an excipient delivery system for pharmaceutical and nutraceutical applications.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or

disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

On November 6, 2019 the Issuer was notified of the default and termination of its joint venture to develop intellectual property for an excipient delivery system for pharmaceutical and nutraceutical applications.

8. Describe the acquisition of new customers or loss of customers.

The Issuer did not acquire or lose any customers during the month of November 2019.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

The Issuer did not have any new developments or effects on intangible products during the month of November 2019.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

The Issuer did not hire, terminate or lay-off any employees during the month of November 2019.

11. Report on any labour disputes and resolutions of those disputes if applicable.

The Issuer had no labour disputes as at November 2019.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

The Issuer is not a party to any legal proceedings.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

The issuer did not incur or repay any indebtedness during November 2019.

FORM 7 – MONTHLY PROGRESS REPORT

January 2015

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
None.			

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

The Issuer did not receive/make any loans from/to Related Persons during November 2019.

16. Provide details of any changes in directors, officers or committee members.

The Issuer had no changes to directors, officers or committee members during the month of November 2019.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The issuer is not aware of any trends, uncertainties, demands, commitments or events which are reasonably likely to have a material effect upon its revenues, income from continuing operations, profitability, liquidity or capital resources or that would cause reported financial information not necessarily to be indicative of future operating results or financial condition.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: December 3, 2019.

Ron Ozols

Name of Director or Senior Officer

/s/ Ron Ozols

Signature

Director

Official Capacity

Issuer Details		For Month Ended	Date of Report
Name of Issuer		November 30, 2019	YY/MM/D 19/12/03
EGF Theramed Health Corp.			
Issuer Address			
5728 East Boulevard			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Vancouver, BC, V6M 4M4			(604) 778-3311
Contact Name		Contact Position	Contact Telephone No.
Ron Ozols		Director	(604) 240-3114
Contact Email Address		Web Site Address	
theramedhealthcorp@gmail.com		www.theramedhealthcorp.com	

FORM 7 – MONTHLY PROGRESS REPORT

January 2015